Form 4: Amneal Pharmaceuticals Director Paul M. Meister Reports Stock Unit Transactions

Director Paul M. Meister reports acquisition and disposal of Amneal Pharmaceuticals Class A Common Stock units.

Summary

• On May 5, 2025, Paul M. Meister, a director of Amneal Pharmaceuticals, reported transactions involving Class A Common Stock.
• Meister acquired 56,361 shares through the vesting of restricted stock units.
• Following the transaction, Meister directly owns 784,053 shares of Class A Common Stock.
• Additionally, Meister was granted 48,747 restricted stock units on May 6, 2025, which will vest on a future date.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports transactions related to stock unit vesting and grants, which are typical for director compensation. There are no explicit positive or negative indicators.

Positives

• The vesting of restricted stock units indicates confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the grant of restricted stock units suggests an expectation of future value appreciation.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates

Keywords

Amneal Pharmaceuticals, Director, Stock Units, Class A Common Stock, Beneficial Ownership, Form 4, Securities